Avadel is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.
Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy.
Dr. Yitong Dong
Dr. Yitong Dong has recently been awarded funding to study custom composite nanocrystals, which could help to create advanced quantum communication technologies. Learn more about this project in this interview.
Roey Elnathan, Ph.D.
We take a closer look at the fusion of nanotechnology and CAR-T therapy through our interview with Dr. Roey Elnathan about a new approach that harnesses the capabilities of nanoneedles to efficiently deliver genetic materials to target cells.
In this interview, Laura-Isabelle, the Director of Sales at Photon etc., talks to AzoNano about how spectral imaging can help improve the next generation of solar cells.
The Verifire™ interferometer system provides fast and reliable measurements of surface form error.
Discover the compact, fast rotary table V-610 for precision testing and manufacture.
The Diamond Interaction Chamber (DIXC) is integral to the NanoGenizer high-pressure homogenizer.